Untapped value in established Pharma and Life Science product portfolios
Established Pharma and Life Science product portfolios have significant untapped value. Manual analysis of launches in new countries, termination of unprofitable products, value optimization as well as potential demand upsides in these complex portfolios is slow, static and unsystematic. This results in inefficiencies and missed opportunities.